CRIS Current Research Information System

ZACCHERINI, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.709
NA - Nord America 5.017
EU - Europa 3.395
SA - Sud America 388
AF - Africa 287
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.809
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.888
VN - Vietnam 2.475
SG - Singapore 1.457
CN - Cina 1.279
IT - Italia 1.036
HK - Hong Kong 515
GB - Regno Unito 456
SE - Svezia 382
DE - Germania 352
BR - Brasile 260
FR - Francia 215
IN - India 211
KR - Corea 167
NL - Olanda 166
BD - Bangladesh 148
FI - Finlandia 144
RU - Federazione Russa 111
IE - Irlanda 108
JP - Giappone 101
CI - Costa d'Avorio 78
CH - Svizzera 76
TG - Togo 76
BG - Bulgaria 69
CA - Canada 69
PH - Filippine 57
ZA - Sudafrica 55
JO - Giordania 46
AT - Austria 45
UA - Ucraina 43
AR - Argentina 42
ES - Italia 41
MX - Messico 40
ID - Indonesia 34
TH - Thailandia 33
PL - Polonia 31
IQ - Iraq 30
EC - Ecuador 27
EE - Estonia 24
BE - Belgio 21
PK - Pakistan 21
TR - Turchia 20
CO - Colombia 19
SA - Arabia Saudita 18
IR - Iran 16
TW - Taiwan 15
SC - Seychelles 14
CL - Cile 13
HR - Croazia 13
EG - Egitto 12
LT - Lituania 11
MY - Malesia 11
UZ - Uzbekistan 11
VE - Venezuela 11
NG - Nigeria 10
NP - Nepal 10
CZ - Repubblica Ceca 8
HU - Ungheria 8
AL - Albania 6
CR - Costa Rica 6
KE - Kenya 6
PY - Paraguay 6
RO - Romania 6
RS - Serbia 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
CD - Congo 5
DZ - Algeria 5
JM - Giamaica 5
MA - Marocco 5
PE - Perù 5
LV - Lettonia 4
NZ - Nuova Zelanda 4
AM - Armenia 3
GR - Grecia 3
IL - Israele 3
MU - Mauritius 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
SN - Senegal 3
UY - Uruguay 3
AZ - Azerbaigian 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
GH - Ghana 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MD - Moldavia 2
MG - Madagascar 2
NI - Nicaragua 2
SY - Repubblica araba siriana 2
VA - Santa Sede (Città del Vaticano) 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
Totale 15.792
Salva come PNG Salva come JPEG
Città #
Singapore 1.045
Ashburn 638
Ho Chi Minh City 533
Hanoi 499
Hong Kong 463
Southend 357
Dong Ket 340
Fairfield 336
Chandler 325
Hefei 308
San Jose 304
Santa Clara 229
Bologna 227
Los Angeles 160
Houston 159
Woodbridge 158
Seoul 141
Beijing 139
Wilmington 133
Seattle 125
Cambridge 121
Boardman 114
Da Nang 113
Helsinki 112
Princeton 112
Dublin 106
Ann Arbor 105
Dallas 103
New York 101
Council Bluffs 95
Milan 89
Lauterbourg 81
Tokyo 81
Abidjan 78
Lomé 76
Sofia 68
Bern 65
Haiphong 56
São Paulo 48
Frankfurt am Main 47
Amman 45
Munich 39
Guangzhou 37
Bengaluru 35
Buffalo 35
Rome 35
Berlin 34
Nanjing 33
Westminster 33
Biên Hòa 32
Redondo Beach 32
Nuremberg 31
Shenyang 29
Jinan 28
Padova 28
San Diego 28
Hải Dương 27
London 26
Toronto 26
Turin 26
Vienna 26
Florence 24
Orem 24
Shanghai 24
Amsterdam 23
Can Tho 23
Zhengzhou 23
Johannesburg 22
Jakarta 21
Rimini 21
Vũng Tàu 21
Warsaw 21
Thái Nguyên 19
Tianjin 19
Chicago 18
Lappeenranta 18
Bangkok 17
Des Moines 17
Mexico City 17
Redmond 17
Chennai 16
Hebei 16
Ninh Bình 16
Phoenix 16
Bến Tre 15
Changsha 15
Hangzhou 15
Naples 15
Saint Petersburg 15
Xi'an 15
Brussels 14
Denver 14
Falkenstein 14
Paris 14
Turku 14
Atlanta 13
Casalecchio di Reno 13
Modena 13
Montreal 13
Quận Bình Thạnh 13
Totale 9.733
Salva come PNG Salva come JPEG
Nome #
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 482
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 433
OS-077 Single-cell RNA sequencing of peripheral blood mononuclear cells in patients with acutely decompensated cirrhosis reveals a specific monocyte subset associated with an increased risk of progression to ACLF 376
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 365
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment 286
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF 272
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 267
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 266
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 262
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 257
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 252
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 244
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 242
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 240
A case of pneumonia and sepsis in cirrhosis as paradigm of the problems in the management of bacterial infections in cirrhosis and of the limitations of current knowledge 234
Low haemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation 220
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 214
Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study 213
Albumin administration in internal medicine: A journey between effectiveness and futility 212
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 211
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 210
Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET) 205
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure 202
Outcomes of patients with alcohol-related cirrhosis referred to a hepatology outpatient clinic 201
Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study) 199
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis 199
A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman 191
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial 190
The analysis of food intake in patients with cirrhosis waiting for liver transplantation: A neglected step in the nutritional assessment 188
Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients 184
A Case of Immune-Mediated Liver Injury Induced by Olaparib 183
Need for deprescribing in hospital elderly patients discharged with a limited life expectancy: The REPOSI study 180
Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. 179
Incidence and clinical implications of abstinence-induced hepatic recompensation in decompensated alcohol-related cirrhosis 178
The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis 178
Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study 177
Role of human albumin in the management of complications of liver cirrhosis. 177
Acute-on-chronic liver failure is a distinct syndrome developing in patients with acute dcompensation of cirrhosis. 176
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 174
Disorders of albumin metabolism in liver diseases. 173
Assessing the role of amino acids in systemic inflammation and organ failure in patients with {ACLF} 173
QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? 172
Real-world experience with long-term albumin in patients with cirrhosis and ascites 168
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis 165
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis 163
Human albumin in the management of complications of liver cirrhosis. 162
Development and validation of a prognostic score to predict mortality in patients with acute on chronic liver failure. 161
Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation 161
Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin. A proposal for a personalized management based on real-world experience 159
Human albumin in the management of complications of cirrhosis. 158
Patients with cirrhosis and ascites treated with long-term albumin: An integrated management proposal based on a real-life study 157
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis 155
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 151
Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease 150
Hyposplenism as a cause of pneumococcal meningoencephalitis in an adult patient with coeliac disease 150
A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic 148
Predictors of clinical courses in patients wih acutely decompensated cirrhosis. An external validation of the PREDICT study 145
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant 144
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology 141
Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis 139
Predictors of clinical trajectories in patients admitted for acutely decompensated cirrhosis: An external validation of the PREDICT study 139
Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature 139
null 138
Long‐term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial 137
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial 137
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1-receptor in a rat model of CCl4-induced advanced cirrhosis. 137
Albumin: Indications in chronic liver disease 137
Approach and management of dysnatremias in cirrhosis 135
Pattern of in-hospital changes in drug use in the older people from 2010 to 2016 131
Management of ascites in patients with cirrhosis: An update 131
Pro: The Role of Albumin in Pre–Liver Transplant Management 128
Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference 127
Defining aging phenotypes and related outcomes: Clues to recognize frailty in hospitalized older patients 124
The Use of Rifaximin in Patients With Cirrhosis 121
Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease 118
Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial 116
Living alone as an independent predictor of prolonged length of hospital stay and non-home discharge in older patients 116
Management of cirrhotic patients with ascites. 115
Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database 112
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium 110
Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects 107
Managing Multiorgan Failure in Acute on Chronic Liver Failure 100
Prevention of cirrhosis complications: Looking for potential disease modifying agents 100
Albumin in hospitalized patients with complications of cirrhosis: Not a suit for all seasons 97
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis 96
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF) 94
Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. 91
null 88
The role and indications of albumin in advanced liver disease 74
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study 72
null 59
Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701] (Journal of Hepatology (2020) 72(4) (688–701), (S0168827819306968), (10.1016/j.jhep.2019.11.009)) 56
Long-term albumin treatment for decompensated cirrhosis in Italy: A propensity score-matched, retrospective, real-world chart analysis 48
Personalised Long‐Term Albumin Treatment Based on Three‐Month Ascites Response in Patients With Decompensated Cirrhosis 46
Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults 38
PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study 26
null 3
null 3
null 1
Totale 16.161
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.212
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.212
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021538 0 0 0 0 0 0 0 0 0 0 0 538
2021/20221.390 157 27 63 84 118 80 35 142 56 74 403 151
2022/20231.415 111 220 77 140 94 114 42 91 235 44 120 127
2023/2024679 32 72 53 80 38 132 31 45 19 36 95 46
2024/20252.460 107 358 207 203 316 138 122 95 96 209 168 441
2025/20267.868 762 611 575 558 607 335 1.532 255 1.301 578 372 382
Totale 16.161